Leiden, 8 January 2025. BIMINI Biotech has closed a €3 million seed investment round to advance its first-in-class therapeutics for haematological cancers.

The financing was led by San Diego-based Torrey Pines Investment, with participation from InnovationQuarter Capital, Libertatis Ergo Holding and a business angel.

Advancing first-in-class WASp modulators

The investment will support the preclinical development of BIMINI’s small-molecule modulators of Wiskott-Aldrich Syndrome Protein (WASp), including further assessment of efficacy, safety and developability.

BIMINI is investigating WASp as a therapeutic target in leukaemia and lymphoma. The company has generated in vitro and in vivo anti-cancer activity across several disease models and is progressing its compounds through lead optimisation and preclinical development.

The programme is supported by drug-discovery capabilities from Expert Systems, including computer-aided drug design and AI-supported approaches across preclinical discovery and early development.

Representatives from Torrey Pines Investment and InnovationQuarter Capital highlighted the scientific rationale and development potential behind BIMINI’s programmes. BIMINI’s management said the financing provides the resources required to move its portfolio towards later-stage preclinical development.

About BIMINI Biotech

BIMINI Biotech is a preclinical-stage biotechnology company based in Leiden, developing first-in-class small-molecule therapeutics targeting WASp in haematological cancers and autoimmune disease.